Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report

BACKGROUND: Lorlatinib has been suggested as the therapeutic option for patients with ROS1-rearranged non-small-cell lung cancer (NSCLC) after ROS1 tyrosine kinase inhibitor (TKI) failure. However, the mechanism mediating lorlatinib resistance has not been well elucidated in ROS1-rearranged NSCLC. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Liu, Jiayin, Zhang, Xue, Han, Jing, Jin, Hui, Wang, Long, Feng, Li, Fan, Zhisong, Zuo, Jing, Wang, Yudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675326/
https://www.ncbi.nlm.nih.gov/pubmed/36411743
http://dx.doi.org/10.2147/CMAR.S387211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675326/
https://www.ncbi.nlm.nih.gov/pubmed/36411743
http://dx.doi.org/10.2147/CMAR.S387211

Ejemplares similares